Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei GMNL-653
- Development stage
- Preclinical
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Topical
01
Overview
**Lactobacillus paracasei GMNL-653** is a specific probiotic strain with demonstrated anti-inflammatory, anti-osteoporotic, and skin health-promoting effects, primarily studied in heat-killed form. It reduces LPS-stimulated IL-6 and NO production in macrophages, inhibits osteoclast-related RANKL expression while enhancing TGF-β and IL-10, restores gut microbiota dysbiosis, maintains intestinal barrier integrity, and protects against ovariectomy-induced bone loss in mice by modulating the gut-bone axis.[1] Additionally, it co-aggregates with scalp fungi like *Malassezia furfur*, inhibits fungal biofilm formation via lipoteichoic acid, upregulates hair growth factors (IGF-1R, VEGF, KGF) in fibroblasts and keratinocytes, and shifts scalp microbiota to improve sebum, dandruff, and hair health when incorporated into shampoos.[2] It also shows potential in psoriasis treatment by suppressing IL-6 and IL-17 cytokines, wound healing, and topical skin repair.[3][4][6] Developed by GenMont Biotech, it is positioned as a safe, non-viable postbiotic for applications in bone health, dermatology, and scalp care.
- Other names
- Lacticaseibacillus paracasei GMNL-653
Beyond the preview
Go deeper on Lactobacillus paracasei GMNL-653.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei GMNL-653.